Literature DB >> 3034317

Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts.

A F Lant.   

Abstract

The emergence of diuretic drugs and angiotensin converting enzyme (ACE) inhibitors ranks amongst the major therapeutic advances of modern medicine. The discovery of these drug groups arose largely by chance, yet each has dramatically influenced the treatment of congestive cardiac failure and arterial hypertension. The central role which diuretics have had in the management of both oedema and hypertension hinges on their ability to induce a net renal excretion of solute and water by selective interference with either active or passive ion transport processes in different segments of the nephron. Irrespective of sites of action, the continued antihypertensive action of diuretics is characterized by a reduction in plasma volume and extracellular fluid (ECF) volume that lasts for as long as the diuretic is given. The mechanism of this effect remains unclear but may involve autoregulatory reactions that leave cardiac output unaltered but maintain a sustained reduction in total peripheral resistance. ACE inhibitors also lower blood pressure by decreasing total peripheral resistance, leaving cardiac output, plasma volume and ECF volume unchanged. The detailed way these haemodynamic changes are achieved remains unknown but inhibition of converting enzyme present not only in the kidney but also in many extrarenal tissue sites, appears important. In both hypertension and cardiac failure, however, the kidney acts as a key target organ for ACE inhibitors. The increased renal vascular resistance and inappropriate renal salt excretion are reversed with enhanced renal blood flow and saluresis. Both angiotensin II (AII) and vasopressin-mediated contraction of glomerular mesangial cells is inhibited, making glomerular filtration more efficient. Reduced aldosterone secondary to blockade of AII formation contributes to saluresis whilst encouraging positive potassium balance. ACE inhibition also impairs breakdown of kinins which may contribute to intrarenal and peripheral vasodilation either on their own or via release of prostaglandins and other vasoactive substances. The hypotensive actions of diuretics are potentiated by ACE inhibition primarily through blockade of AII formation and prevention of secondary aldosteronism. In combination, these drugs permit low doses to be used because of their synergistic effects. Caution has to be exercised whenever ACE inhibition is used, without and especially with diuretics, in the management of renovascular hypertension and other low-perfusion states. In these circumstances, AII plays an important autoregulatory role in preserving glomerular filtration through an increase in post-glomerular resistance.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034317      PMCID: PMC1386044          DOI: 10.1111/j.1365-2125.1987.tb03120.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  68 in total

1.  Diuretics in perspective.

Authors:  K H Beyer
Journal:  J Clin Pharmacol       Date:  1977-10       Impact factor: 3.126

2.  Antihypertensive and biochemical effects of chlorthalidone.

Authors:  M G Tweeddale; R I Ogilvie; J Ruedy
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

3.  An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients.

Authors:  H Gavras; H R Brunner; J H Laragh; J E Sealey; I Gavras; R A Vukovich
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

4.  Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure.

Authors:  H R Brunner; H Gavras; J H Laragh
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

5.  Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme.

Authors:  J G Collier; B F Robinson; J R Vane
Journal:  Lancet       Date:  1973-01-13       Impact factor: 79.321

6.  Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung.

Authors:  Y S Bakhle
Journal:  Nature       Date:  1968-11-30       Impact factor: 49.962

7.  Furosemide effect on isolated perfused tubules.

Authors:  M Burg; L Stoner; J Cardinal; N Green
Journal:  Am J Physiol       Date:  1973-07

8.  A potent reversible inhibitor of carboxypeptidase A.

Authors:  L D Byers; R Wolfenden
Journal:  J Biol Chem       Date:  1972-01-25       Impact factor: 5.157

9.  A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients.

Authors:  J Anderson; B E Godfrey; D M Hill; A D Munro-Faure; J Sheldon
Journal:  Q J Med       Date:  1971-10

10.  The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat.

Authors:  S H Ferreira; J R Vane
Journal:  Br J Pharmacol Chemother       Date:  1967-06
View more
  5 in total

Review 1.  The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.

Authors:  Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

2.  Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril.

Authors:  D I Friedman; G L Amidon
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

3.  Enalapril and hydrochlorothiazide in hypertensive Africans.

Authors:  A A Ajayi; E A Oyewo; G O Ladipo; A Akinsola
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic renal failure.

Authors:  H J Kloke; F T Huysmans; J F Wetzels; H E Sluiter; C H Kleinbloesem; R A Koene
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 5.  Treating stage 2 hypertension.

Authors:  Thomas D Giles; Barry J Materson
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.